HS research update (2026-10-01): What’s new on PubMed?

Canonical URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-01/
Markdown URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-01.md
Plain text URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-01.txt
Language: en
Category: Research
Published: 2026-10-01
Last updated: 2026-10-01
Last editorially reviewed: 2026-10-01
Next scheduled review: 2027-10-01

Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert)
Scientific editor: Dr. rer. nat. Dennis Alexander Kwiatkowski
Reviewer qualifications: Biochemist, Scientific Writer and Pharma Expert
Review scope: Scientific literature, clinical guidelines, sources, and editorial clarity
Clinical reviewer: No independent clinical review
Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, jak inhibitor, pain, quality of life, surgery, wound care
A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice.

Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions.

Article

Publication overview

This update includes 22 PubMed publications with abstracts from the monitoring window 2026-09-17 to 2026-10-01. The most common themes are biologics, pain, wound care, quality of life, comorbidities.

- Compared with the previous update: not automatically assessed.
- No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window.
- This is a research overview, not a guideline update or medical recommendation.

Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities.

- Hidradenitis Suppurativa: Part of a Tetrad of Follicular Occlusion Disorders.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: UNLABELLED: Follicular occlusion disorders (FOD) represent a tetrad of chronic, recurrent inflammatory conditions united by a common pathophysiologic mechanism: follicular hyperkeratosis leading to occlusion, rupture,… What makes it notable here is that it approaches HS through biologics, quality of life, pain, wound care, surgery. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42759045 (https://pubmed.ncbi.nlm.nih.gov/42759045/))
- Pathogenesis of hidradenitis suppurativa: From susceptibility to chronicity.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by painful nodules, abscesses, draining tunnels and scarring, with substantial effects on quality of life. Although the the… What makes it notable here is that it approaches HS through quality of life, biologics, pain. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42786922 (https://pubmed.ncbi.nlm.nih.gov/42786922/))
- Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa is a chronic, inflammatory skin disease that predominantly affects women of reproductive age and may require continuous therapeutic control during pregnancy and lactation. This review summariz… What makes it notable here is that it approaches HS through biologics, jak inhibitor, comorbidities. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42768237 (https://pubmed.ncbi.nlm.nih.gov/42768237/))
- A Silent Killer in an Unlikely Place: Necrotizing Fasciitis of the Breast.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Primary necrotizing fasciitis (NF) of the breast is a rare, life-threatening soft tissue infection that is frequently misdiagnosed due to its non-specific early presentation and uncommon anatomical location.Objective:… What makes it notable here is that it approaches HS through biologics, pain, wound care. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42764423 (https://pubmed.ncbi.nlm.nih.gov/42764423/))
- IL-17 treatment and side-effect management: This paper focuses on mucocutaneous candidiasis during bimekizumab therapy for HS. The new angle is practical: how prevention and early management of a known IL-17-pathway adverse event might affect tolerability and treatment persistence. (PMID 42812940 (https://pubmed.ncbi.nlm.nih.gov/42812940/))

Featured publication

The featured paper is Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials. in Skin health and disease (PMID 42812940 (https://pubmed.ncbi.nlm.nih.gov/42812940/)). The abstract mainly says this: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that primarily affects the intertriginous regions, causing manifestations such as inflammatory nodules, abscesses and scarring. OBJECTIVES: To sys…

Why it stands out: it connects to the priority themes biologics, pain and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that Its strength depends on the quality and comparability of the included studies, and an abstract does not expose every methodological weakness.

What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right for you personally. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

What we don’t know / limitations

- This update includes only PubMed items with an abstract (without an abstract, safe summarization is limited).
- Studies vary widely (design, populations, outcome measures).
- This update provides no treatment advice and cannot assess individual risk.

Important: decisions belong in clinician conversations

This article is an editorial overview and is not medically reviewed. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

FAQ

Why are there only a few new publications here?
This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

Does a new paper mean my treatment should change?
No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

Why emphasize limitations so much?
Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available).

References

1. 'My HS is significantly impacted by my cycle': a cross-sectional study exploring the impact of menstruation and pregnancy on hidradenitis suppurativa. - Skin health and disease, 2026 — PMID 42812963 · DOI 10.1093/skinhd/vzag087 · PMCID PMC13623445 - https://pubmed.ncbi.nlm.nih.gov/42812963/
2. Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials. - Skin health and disease, 2026 — PMID 42812940 · DOI 10.1093/skinhd/vzag102 · PMCID PMC13623431 - https://pubmed.ncbi.nlm.nih.gov/42812940/
3. Hidradenitis Suppurativa: Part of a Tetrad of Follicular Occlusion Disorders. - Advances in skin & wound care, 2026 — PMID 42759045 · DOI 10.1097/ASW.0000000000000523 - https://pubmed.ncbi.nlm.nih.gov/42759045/
4. Large language models in Hidradenitis suppurativa: strong empathy, weak exposome awareness. - Cutaneous and ocular toxicology, 2026 — PMID 42815942 · DOI 10.1080/15569527.2026.2740528 - https://pubmed.ncbi.nlm.nih.gov/42815942/
5. Functional evaluation of CAR-T anti-CD123 from immune-mediated inflammatory diseases patients for novel pDCs-targeted immunotherapy. - The Journal of allergy and clinical immunology, 2026 — PMID 42815783 · DOI 10.1016/j.jaci.2026.08.031 - https://pubmed.ncbi.nlm.nih.gov/42815783/
6. Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review. - Dermatology and therapy, 2026 — PMID 42809075 · DOI 10.1007/s13555-026-01930-8 - https://pubmed.ncbi.nlm.nih.gov/42809075/
7. Type 1 Diabetes is Associated With Increased Therapeutic Burden in Hidradenitis Suppurativa: A Multicenter Retrospective Matched Case-Control Study. - Journal of cutaneous medicine and surgery, 2026 — PMID 42803015 · DOI 10.1177/12034754261484189 - https://pubmed.ncbi.nlm.nih.gov/42803015/
8. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Hidradenitis Suppurativa: A Narrative Review of Emerging Evidence. - Clinics in dermatology, 2026 — PMID 42790605 · DOI 10.1016/j.clindermatol.2026.09.029 - https://pubmed.ncbi.nlm.nih.gov/42790605/
9. Pathogenesis of hidradenitis suppurativa: From susceptibility to chronicity. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42786922 · DOI 10.1111/jdv.70765 - https://pubmed.ncbi.nlm.nih.gov/42786922/
10. Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa. - Expert opinion on therapeutic targets, 2026 — PMID 42779274 · DOI 10.1080/14728222.2026.2738341 - https://pubmed.ncbi.nlm.nih.gov/42779274/
11. Trephine Grattage: Optimizing the Surgical Approach for Acute Abscesses in Hidradenitis Suppurativa. - International journal of dermatology, 2026 — PMID 42779007 · DOI 10.1111/ijd.70696 - https://pubmed.ncbi.nlm.nih.gov/42779007/
12. GLP-1 Receptor Agonists in Dermatology: Prescribing Frameworks, Access, and the Emerging Pipeline. - Clinics in dermatology, 2026 — PMID 42777891 · DOI 10.1016/j.clindermatol.2026.09.018 - https://pubmed.ncbi.nlm.nih.gov/42777891/
13. Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review. - Dermatology and therapy, 2026 — PMID 42768237 · DOI 10.1007/s13555-026-01909-5 - https://pubmed.ncbi.nlm.nih.gov/42768237/
14. Clinically relevant evidence on imaging and artificial intelligence in hidradenitis suppurativa. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42765561 · DOI 10.1111/jdv.70716 - https://pubmed.ncbi.nlm.nih.gov/42765561/
15. A Silent Killer in an Unlikely Place: Necrotizing Fasciitis of the Breast. - Surgical infections, 2026 — PMID 42764423 · DOI 10.1177/10962964261490203 - https://pubmed.ncbi.nlm.nih.gov/42764423/
16. CUDERMA project: Delphi consensus on quality indicators for certification of dermatology units providing care for hidradenitis suppurativa. - Actas dermo-sifiliograficas, 2026 — PMID 42762905 · DOI 10.1016/j.ad.2026.104743 - https://pubmed.ncbi.nlm.nih.gov/42762905/
17. Consensus recommendations for optimal trial design and reporting of core domains in urate-lowering therapy trials for gout: A Delphi study. - Seminars in arthritis and rheumatism, 2026 — PMID 42785113 · DOI 10.1016/j.semarthrit.2026.153079 - https://pubmed.ncbi.nlm.nih.gov/42785113/
18. Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study. - Dermatology (Basel, Switzerland), 2026 — PMID 42758664 · DOI 10.1159/drm/ackag020 - https://pubmed.ncbi.nlm.nih.gov/42758664/
19. Beyond the Skin: Ocular Manifestations in Hidradenitis Suppurativa - A Systematic Review. - Ocular immunology and inflammation, 2026 — PMID 42758116 · DOI 10.1080/09273948.2026.2736180 - https://pubmed.ncbi.nlm.nih.gov/42758116/
20. Dietary Modulation of microRNAs as a Potential Nutritional Strategy in Inflammatory and Autoimmune Skin Diseases: A Narrative Review. - Cells, 2026 — PMID 42782741 · DOI 10.3390/cells15181640 · PMCID PMC13605420 - https://pubmed.ncbi.nlm.nih.gov/42782741/
21. Emerging Topical Therapies and Skin Care Management for Hidradenitis Suppurativa. - Skin therapy letter, 2026 — PMID 42805594 - https://pubmed.ncbi.nlm.nih.gov/42805594/
22. Presentations of Cutaneous Disease in Various Skin Pigmentations: Hidradenitis Suppurativa. - HCA healthcare journal of medicine, 2026 — PMID 42751462 · DOI 10.36518/2689-0216.2330 · PMCID PMC13581336 - https://pubmed.ncbi.nlm.nih.gov/42751462/